Back to Research Home
CNMDCONMED Corporation
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · Small
$49.25−0.38%
As of 23 Oct 2026Mkt cap $1.5B
Stage 13
AVOID
Fundamentals
37.9/75
Technical
5.9/15
Independent
43.8/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +9.0%
- 3M
- +13.2%
- 6M
- +28.5%
- 1Y
- +1.0%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 26.6xHist median 18.5x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 11.4x
- FCF yield
- 8.8%
Quality
- ROIC
- 3.7%
- Operating margin
- 9.7%
- FCF margin
- 11.0%
- Current ratio
- 2.1x
Growth
- Revenue growth
- +5.2%Latest FY YoY
- Revenue CAGR
- +8.0%
- EPS CAGR
- −6.1%
- FCF CAGR
- +11.7%
Capital
- Share-count trend
- −0.6%3Y annualised
- Net debt
- $793M4.6x OCF
Annual trend
- CAGR 2021–2025
- +8.0%
- Latest · 2025
- $1B
- YoY
- +5.2%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL DECELERATION
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-28
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded